menu
    • menu
    [{"orgOrder":0,"company":"Acerta Pharma","sponsor":"Ascentage Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Acalabrutinib","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Acerta Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Acerta Pharma \/ Ascentage Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Acerta Pharma \/ Ascentage Pharma"},{"orgOrder":0,"company":"Acerta Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Acerta Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Acerta Pharma \/ Acerta Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Acerta Pharma \/ Acerta Pharma"},{"orgOrder":0,"company":"Acerta Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Acerta Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Acerta Pharma \/ Acerta Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Acerta Pharma \/ Acerta Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Acerta Pharma

    Menu

    Acerta Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Acerta Pharma

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Acerta Pharma

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Acalabrutinib,Bendamustine Hydrochloride,Rituximab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : AstraZeneca

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CALQUENCE Plus Chemoimmunotherapy Reduces Progression Risk in Lymphoma Trial

                            Details : Calquence (acalabrutinib) is a next-generation, selective inhibitor of bruton’s tyrosine kinase (BTK). It is being evaluated for the treatment of mantle cell lymphoma in adults.

                            Brand Name : Calquence

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 16, 2024

                            Lead Product(s) : Acalabrutinib,Bendamustine Hydrochloride,Rituximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : AstraZeneca

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Acerta Pharma

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Acerta Pharma

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Acalabrutinib,Bendamustine Hydrochloride,Rituximab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : AstraZeneca

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CALQUENCE Combo Shows Significant Improvement in Progression-Free Survival in Lymphoma

                            Details : Calquence (acalabrutinib) is a next-generation, selective inhibitor of bruton’s tyrosine kinase (BTK). It is being evaluated for the treatment of mantle cell lymphoma in adults.

                            Brand Name : Calquence

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 02, 2024

                            Lead Product(s) : Acalabrutinib,Bendamustine Hydrochloride,Rituximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : AstraZeneca

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Acerta Pharma

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Acerta Pharma

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lisaftoclax,Acalabrutinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Ascentage Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Ascentage Pharma Enters Clinical Collaboration to Evaluate the Combination of Bcl-2 and BTK Inhibitors

                            Details : Companies will study the combination of Ascentage's APG-2575 and Acerta's CALQUENCE® (acalabrutinib), evaluating the efficacy and safety of this combination therapy in patients with relapsed/refractory (r/r) chronic lymphocytic leukemia (CLL)/small lymp...

                            Brand Name : APG-2575

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            June 21, 2020

                            Lead Product(s) : Lisaftoclax,Acalabrutinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Ascentage Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth